Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: May 30, 2014

NEW YORK (GenomeWeb) – Ascendant Dx said this week it has named Patricia Beckmann as CSO and chief business officer, and that Mark Boguski and Isaac Kohane have joined its scientific advisory board.

Beckmann is a co-inventor of the rheumatoid arthritis drug Enbrel, was founder and managing director of BioStrategy, and was president and executive director of the Oregon
Translational Research Development Institute. She also was CSO at Homestead Clinical (now Integrated Diagnostics), a proteomic biomarkers company, and she worked vetting biotechnology venture investment opportunities with Vulcan Capital.

Boguski currently is on the faculty of Harvard Medical School and is chief medical officer of Genome Health Solutions. He previously founded the Genomic Medicine Initiative at Beth Israel Deaconess Medical Center and was a faculty member at the Johns Hopkins School of Medicine and National Institutes of Health, and he is a former vice president of Novartis.

Kohane is a professor of pediatrics and technology at HMS, and is co-director of the Center for Biomedical Informatics and director of the Boston Children's Hospital Informatics Program. He also heads several NIH-funded projects that seek to translate genomic research into clinical practice.

Illumina stockholders this week voted to re-elect four members of its board of directors, approving three-year terms on the board for Daniel Bradbury, Robert Epstein, and Roy Whitfield, and a two-year term for Francis deSouza.

BioMérieux this week appointed two new independent directors, Agnès Lemarchand and Philippe Gillet. Lemarchand and Gillet are replacing Georges Hibon and Michel Angé, who did not wish to renew their terms on the company's board.

Lemarchand has served as CEO of Industrie Biologique Française, a joint venture between the Rhône-Poulenc group and Institut Mérieux. She has also served as chairman and CEO of Prodical, a subsidiary of the Ciments Français group; and chairman and CEO of the Lafarge group's lime business.

Gillet was a professor of geophysics at the University of Rennes prior to becoming director of l’Ecole Normale Supérieure de Lyon, where he was also a professor of earth sciences. In addition, from May 2007 to April 2010 he served as chief of staff for the French Minister of Higher Education and Research. He subsequently joined l’Ecole Polytechnique Fédérale of Lausanne, where he serves as vice president for academic affairs.

Exosome Diagnostics has named William Kelly as CFO.

Kelly has worked for RepliGen for the past six years, serving as the principal financial officer there for more than five years. He has also served as corporate controller of Haemonetics, and has worked for Deloitte & Touche.

Cancer Treatment Centers of America has appointed Maurie Markman as president of its medicine and science unit. Previously, Markman was senior VP of clinical affairs and national director of medical oncology at CTCA.

In his new position, Markman will lead CTCA's national clinical team. He is an expert in the field of medical oncology and clinical research, and has conducted pioneering work in advanced genomic testing, CTCA CEO Gerard van Grinsven said in a statement. Throughout his career, Markman has held various leadership roles at many leading cancer institutions, including The Cleveland Clinic, the University of Texas MD Anderson Cancer Center, and The Ohio State University.

Enzo Biochem said this week it has appointed James O'Brien as senior VP of finance, succeeding Andrew Crescenzo, who is departing the company. Enzo also said that former Chief Operations Officer Andrew Whiteley also has left the company.

O'Brien most recently was VP and corporate controller for Actavis; has held senior finance posts at Nycomed US, Aptuit, Purdue Pharma, and Bristol Myers Squibb; and began his career as an accountant at Pricewaterhouse Coopers.

The Australian molecular diagnostics firm Genetic Technologies has appointed Eutillio Buccilli as CFO. Buccilli has over 35 years of senior management experience in financial services, contracting, and property and retail industries in the US and Australia. He has held senior management posts at General Electric, Computer Science Corporation, Coles Myer, and Challenger Limited.

GNS Healthcare has added several new members to its scientific advisory board.

The list includes James Robins, a professor of epidemiology at the Harvard School of Public Health. His research efforts focus on the development of analytic methods for drawing causal inferences from complex observational and randomized studies with time-varying exposures or treatments.

Also joining GNS' SAB is Isaac Kohane, who is the director of the Boston Children's Hospital's Informatics Program and a professor of pediatrics, health sciences, and technology at HMS.

Singulex has appointed Peter Heseltine chief medical officer.

Heseltine is professor of Clinical Medicine at the University of California, Irvine. Previously he was senior vice president and chief medical officer at Prometheus Laboratories. He also held executive positions at Beckman Coulter and Quest Diagnostics.

ProteoMedix has named Mark Emberton as a clinical advisor.

Emberton is director of the Division of Surgery and Interventional Science at University College, London as well as a founding partner of London Urology Associates.

George Komatsoulis has left the National Cancer Institute to work as a senior bioinformatics specialist at the National Center for Biotechnology Information.

Previously, he was the deputy director of the NCI's Center for Biomedical Informatics and
Information Technology (CBIIT). He's also served as acting chief information officer and interim director for CBIIT.

Juli Klemm is serving as acting deputy director for CBIIT while the agency searches for a replacement.

Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.